ROIVANT SCIENCES LTD. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ROIVANT SCIENCES LTD. (ROIV) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$533.00 million for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-02-13
- ROIVANT SCIENCES LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-06-30 was -$117.56M.
- ROIVANT SCIENCES LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-06-30 was -$133.30M, a 400.75% decline year-over-year.
- ROIVANT SCIENCES LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-06-30 was $44.32M.
- ROIVANT SCIENCES LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$67.64M.
- ROIVANT SCIENCES LTD. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$127.58M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$533.00M 10-Q · filed 2023-02-13 | |||
| 2022-09-30 | -$461.39M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$117.56M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | -$67.64M 10-K · filed 2022-06-28 | |||
| 2021-12-31 | $84.46M 10-Q · filed 2023-02-13 | |||
| 2021-09-30 | $367.45M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$133.30M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$127.58M 10-K · filed 2022-06-28 | |||
| 2020-12-31 | -$116.13M 10-Q · filed 2022-02-14 | |||
| 2020-09-30 | $120.37M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $44.32M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |